Standard Chem. & Pharm. Co., Ltd. : Ingredients Company Profile, SWOT & Financial Report

Document Sample
Standard Chem. & Pharm. Co., Ltd. : Ingredients Company Profile, SWOT & Financial Report Powered By Docstoc
					Standard Chem. & Pharm. Co., Ltd.

_________________________________________________________________________________



Standard Chem. & Pharm. Co., Ltd.                                                  Financial Snapshot

                                                                                   Operating Performance
Fast Facts
                                                                                   The company reported revenue of US$91.74 million
Headquarters Address                    No.6-20, Sinying City, 73055,Taiwan
                                                                                   during the fiscal year 2010 (2010). The company's
                                                                                   revenue grew at a CAGR of 11.60% during 2006–
Telephone                               + 886 6 6361511
                                                                                   2010, with an annual growth of 32.80% over 2009. In
                                                                                   2010, the company recorded an operating margin of
Fax                                     + 886 6 6329953                            11.02%, as against 13.25% in 2009.

Website                                 www.standard.com.tw
                                                                                   Revenue and Margins
Ticker Symbol, Stock Exchange           1720, Taiwan Stock Exchange

Number of Employees                     830

Fiscal Year End                         December

Revenue (in US$ million)                91.74

Revenue (in TWD million)                2,894.48




SWOT Analysis                                                                      Return on Equity

Strengths                               Weaknesses                                 The company recorded a return on equity (ROE) of
                                                                                   7.78% for 2010, as compared to its peers, Takeda
Broad product portfolio                 Decline in margins                         Pharmaceutical Company Limited (Ticker: 4502),
                                                                                   Astellas Pharma Inc. (Ticker: 4503) and China
                                                                                   Chemical & Pharmaceutical Co. Ltd. (Ticker: 1701),
Focus on quality and food safety        Declining liquidity position               which recorded ROEs of 14.04%, 11.60% and 7.90%
                                                                                   respectively. The company reported an operating
Geographically diversified operations   Weakening solvency position                margin of 11.02% in 2010.

Strengthening efficiency                                                           Return on Equity

Opportunities                           Threats

Growing cosmetics market in Asia        Rising labor costs in the US

Increase in healthcare spending         Consolidation within the industry

Joint venture with DIA Pharmaceutical
                                      Illicit pharmaceutical ingredients trading
Co Ltd




                                                                                   Liquidity Position

                                                                                   The company reported a current ratio of 2.28 in 2010,
                                                                                   as compared to its peers, Takeda Pharmaceutical
                                                                                   Company Limited, Astellas Pharma Inc. and China
                                                                                   Chemical & Pharmaceutical Co. Ltd., which recorded
                                                                                   current ratios of 3.67, 3.57 and 1.21 respectively. As
                                                                                   of December 2010, the company recorded cash and
                                                                                   short-term investments of worth US$34.44 million,
                                                                                   against zero current debt. The company reported a
                                                                                   debt to equity ratio of 0.33 in 2010 as compared to its
                                                                                   peers, Takeda Pharmaceutical Company Limited,
                                                                                   Astellas Pharma Inc. and China Chemical &
                                                                                   Pharmaceutical Co. Ltd., which recorded debt to
                                                                                   equity ratios of 0.01, 0.00 and 0.35 respectively.




_______________________________________________________________________________
				
DOCUMENT INFO
Description: Canadean's "Standard Chem. & Pharm. Co., Ltd. : Ingredients Company Profile, SWOT & Financial Report" contains in depth information and data about the company and its operations. The profile contains a company overview, business description, competitive benchmarking, SWOT analysis, mergers & acquisitions, key facts, information on products and services, details of locations and subsidiaries.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER Canadean
Canadean has long held a reputation with FMCG markets for providing specialist business information by conducting detailed industry and consumer research, supported by insightful value-added analysis. We cover the entire spectrum of the consumer value chain from suppliers, brand owners, distribution channels and consumer insight. By researching markets in a holistic way, Canadean’s research methodology enables clients to make informed strategical decisions that are founded on robust and reliable data and market insights. We specialise in online survey panels, qualitative and quantitative in-country research, industry analysis and consultancy. Canadean’s dedicated in-country researchers and analysts have an industry background in marketing, market research, consulting and advanced statistical expertise. They are well positioned in the industries themselves and therefore, best placed to ask the right questions of the right people. This network of professional researchers stretches across more than 80 countries, enabling Canadean to conduct unique research via our trusted business communities.